Literature DB >> 28164207

Incremental value of 99mTc-HYNIC-TOC SPECT/CT over whole-body planar scintigraphy and SPECT in patients with neuroendocrine tumours.

Mate Trogrlic1, Stanko Težak.   

Abstract

AIM: The aim of this study was to evaluate the additional value of 99mTc-HYNIC-TOC SPECT/CT over planar whole-body (WB) scintigraphy and SPECT alone in the detection and accurate localisation of neuroendocrine tumour (NET) lesions.
METHODS: This study included 65 patients with a definitive histological diagnosis of NET prior to scintigraphy. Planar WB scintigraphy, SPECT, and SPECT/CT images were acquired at 4 h post-administration of 670 MBq 99mTc-HYNIC-TOC. Additional SPECT images at 10 min after tracer administration were also acquired. Clinical and imaging follow-up findings were considered as the reference standards (minimum follow-up period, 15 months). Patient and lesion-based analyses of the efficacies of the imaging modalities were performed.
RESULTS: While 38 patients exhibited metastasis of NETs, 27 presented no evidence of metastasis. Upon patient-based analysis, the sensitivity and specificity of SPECT/CT were found to be 88.9 and 79.3 %, respectively. The diagnostic accuracies of WB scintigraphy, 4h-SPECT, and SPECT/CT were 72.3, 73.8, and 84.6 %, respectively. The area under curve (AUC) value for SPECT/CT (0.84) was the highest, followed by those for 4h-SPECT (0.75) and WB scintigraphy (0.74). The accuracy and AUC values of SPECT/CT were significantly better compared to those of WB scintigraphy (p < 0.001), 10 min-SPECT (p < 0.001), and 4 h-SPECT (p = 0.001). The findings of SPECT/CT led to the change in treatment plan of 11 patients (16.9 %).
CONCLUSION: The sensitivity and diagnostic accuracy of SPECT/CT in the evaluation of NET lesions outperforms planar WB imaging or SPECT alone.

Entities:  

Keywords:  neuroendocrine tumours; receptors somatostatin; technetium 99m EDDA-HYNIC-Tyr(3)-octreotide

Mesh:

Substances:

Year:  2017        PMID: 28164207     DOI: 10.3413/Nukmed-0851-16-10

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  3 in total

1.  The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?

Authors:  Mirela Gherghe; Alexandra Maria Lazăr; Adina Elena Stanciu; Mario-Demian Mutuleanu; Maria-Carla Sterea; Cristina Petroiu; Laurenția Nicoleta Galeș
Journal:  Cancers (Basel)       Date:  2022-05-31       Impact factor: 6.575

2.  99mTc-EDDA/HYNIC-TOC is a New Opportunity in Neuroendocrine Tumors of the Lung (and in other Malignant and Benign Pulmonary Diseases).

Authors:  Vittorio Briganti; Vincenzo Cuccurullo; Valentina Berti; Giuseppe D Di Stasio; Flavia Linguanti; Francesco Mungai; Luigi Mansi
Journal:  Curr Radiopharm       Date:  2020

3.  99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma.

Authors:  Camila Mosci; Fernando V Pericole; Gislaine B Oliveira; Marcia T Delamain; Maria E S Takahashi; José Barreto C Carvalheira; Elba C S C Etchebehere; Allan O Santos; Eliana C M Miranda; Mariana C L Lima; Barbara J Amorim; Carmino A de Souza; Irene Lorand-Metze; Celso D Ramos
Journal:  Nucl Med Commun       Date:  2020-10       Impact factor: 1.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.